Literature DB >> 6293043

Antacid therapy--changes in mineral metabolism.

P Herzog, K H Holtermüller.   

Abstract

Antacid ingestion may lead to side-effects related to their chemical composition. Aluminum hydroxide may cause the phosphate depletion syndrome even during short-term administration of high doses in patients at high risk, such as alcoholics. Long-term intake may lead to bone demineralization and to osteomalacia. Fluoride complexing in the gut and prevention of fluoride absorption may be an additional factor. The clinical relevance of aluminum absorption in patients with normal renal function is not clear. In contrast, in patients with renal failure, aluminum hydroxide ingestion may contribute to an increasing hyperaluminemia. Hyperaluminemia and tissue deposition of aluminum in these patients may contribute to the dialysis-associated encephalopathy. Magnesium hydroxide causes an alkalinization of the urine due to magnesium absorption and urinary excretion. Thus, in renal insufficiency, a life-threatening hypermagnesemia may develop if magnesium-aluminum-containing antacids are prescribed. The milk-alkali syndrome, rarely observed nowadays, may be caused by calcium carbonate- and sodium bicarbonate-containing antacids. Hypercalciuria and alkaluria predispose to nephrolithiasis. The possibility that these disturbances in mineral metabolism will develop in patients with normal renal function is unlikely unless there is an abuse of these "over the counter" antacids.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6293043

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  2 in total

1.  Enhanced bilirubin binding to different mammalian erythrocytes in the presence of magnesium ions.

Authors:  M K Ali; M U Siddiqui; S Tayyab
Journal:  Indian J Clin Biochem       Date:  2001-01

2.  Knowledge and awareness of nonpharmacist salespersons regarding over-the-counter drug use in patients with chronic kidney disease in Japan.

Authors:  Yuki Kondo; Yoichi Ishitsuka; Nobuhiro Kawabata; Nobuhide Iwamoto; Risa Takahashi; Yuki Narita; Daisuke Kadowaki; Sumio Hirata; Satoru Uchino; Tetsumi Irie
Journal:  PLoS One       Date:  2019-03-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.